Andy Hsieh

Khalil Fenina

Matthew Keller

Tsan-Yu Hsieh

- FibroGen completed the sale of its China subsidiary to AstraZeneca for approximately **$220 million**, consisting of **$85 million** in enterprise value and approximately **$135 million** in net cash.  **[921299_9d3652b8bace4fa5b34e746517c3eaa7_0]** **[921299_9d3652b8bace4fa5b34e746517c3eaa7_1]** 
- This transaction substantially strengthens FibroGen's financial position, extending its cash runway into **2028**, and allowed for the repayment of an approximately **$81 million** term loan to Morgan Stanley Tactical Value.  **[921299_9d3652b8bace4fa5b34e746517c3eaa7_0]** **[921299_9d3652b8bace4fa5b34e746517c3eaa7_1]** 
- The company remains on track to initiate the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in **3Q 2025** and intends to file the Phase 3 protocol for roxadustat in anemia associated with lower-risk MDS in **4Q 2025**.  **[921299_9d3652b8bace4fa5b34e746517c3eaa7_0]** **[921299_9d3652b8bace4fa5b34e746517c3eaa7_1]**

FIBROGEN (FGEN)